Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
0 hedge funds and large institutions have $0 invested in Concert Pharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 85 closing their positions.
100% less funds holding
Funds holding: 85 → 0 (-85)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $203M → $0 (-$203M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 85
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$25.8M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$21.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$11.2M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$10.1M |
| 5 |
Millennium Management
New York
|
-$8.42M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
76
Aquatic Capital Management
Chicago,
Illinois
| – | -$12K | -2,000 | Closed |
|
77
Fidelity Investments
Boston,
Massachusetts
| – | -$11.7K | -1,997 | Closed |
|
78
Group One Trading
Chicago,
Illinois
| – | -$11K | -1,891 | Closed |
|
|
SPIA
79
Steward Partners Investment Advisory
New York
| – | -$5.65K | -968 | Closed |
|
|
CUAMC
80
China Universal Asset Management Company
Shanghai,
China
| – | -$2.84K | -487 | Closed |
|
81
BNP Paribas Financial Markets
Paris,
France
| – | -$2.31K | -395 | Closed |
|
82
Wells Fargo
San Francisco,
California
| – | -$1.72K | -294 | Closed |
|
83
Daiwa Securities Group
Tokyo,
Japan
| – | -$1K | -193 | Closed |
|
|
AWM
84
AllSquare Wealth Management
Albany,
New York
| – | -$876 | -150 | Closed |
|
|
DWA
85
Delos Wealth Advisors
Dallas,
Texas
| – | -$193 | -33 | Closed |
|
CNCE Hedge Fund Activity: Q1 2023 in Review
0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q1 2023, worth a combined $0 — down 100% from $203M a quarter earlier.
Sellers outnumbered buyers: 85 funds closed out of CNCE and 0 opened new positions — a net loss of 85 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Kynam Capital Management, exiting entirely with an estimated $25.8M sold.
- 0 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q1 2023, down from 85 in Q4 2022.
- Funds reported $0 of Concert Pharmaceuticals, Inc. stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new Concert Pharmaceuticals, Inc. positions in Q1 2023 and 85 closed out, a net change of -85 holders.
- The largest Concert Pharmaceuticals, Inc. seller in Q1 2023 was Kynam Capital Management, an estimated $25.8M sold.
Based on aggregated 13F filings for Q1 2023.